TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00351052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (placebo) bid.
Study: NCT00683462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00683462
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 5 mg/day (once a day) for 2 weeks
Study: NCT00683462
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 50 mg/day (once a day) for 2 weeks
Study: NCT01474252
Drug: RSI
Normalized name: Lorsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg
Study: NCT03085797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
Study: NCT02415907
Drug: [ethyl-1-14C]-idalopirdine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
Study: NCT02415907
Drug: [benzyl-7-14C]-idalopirdine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
Study: NCT02147015
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02147015
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02147015
Drug: Inhaled corticosteroid (ICS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02147015
Drug: Long-Acting Muscarinic Antagonists(LAMA)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02147015
Drug: Short-acting beta2-agonist (SABA)
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01837823
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
Study: NCT02291458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 gram placebo / day for 6 weeks
Study: NCT02147015
Drug: long-acting beta2-agonist (LABA)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02101957
Drug: RP103
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02054104
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
Study: NCT02054104
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
Study: NCT02101957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867815
Drug: Diagnostic procedures
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
Study: NCT00120419
Drug: mycophenol mofetil (MMF, Cellcept®) 500 mg BID
Normalized name: mycophenolate mofetil 500 MG
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01801228
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00752206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Agent
Study: NCT01046838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet 3 times daily for 9 weeks
Study: NCT01497288
Drug: INFS (Intranasal Fentanyl Spray)
Normalized name: fentanyl Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Fentanyl Spray
Study: NCT00004554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02586649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a non-active inhalation capsule .
Study: NCT00710580
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ placebo injections for ABT-874 and etanercept
Study: NCT02896413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion
Study: NCT04374942
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
Study: NCT00001213
Drug: Cysteamine
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03374852
Drug: mFOLFIRNOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRNOX (given immediately after CPI-613 administration):
Study: NCT00373113
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Study: NCT03736772
Drug: LY3090106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03736772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00674713
Drug: Physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04335136
Drug: Physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with placebo intravenously twice daily (BID).
Study: NCT00787618
Drug: 50 mg Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00587496
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose placebo capsule, six per day for 30 days
Study: NCT01683565
Drug: LCPUFA oil supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)
Study: NCT00965562
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
Study: NCT00965562
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of calcium to be taken for 5 menstrual cycles.
Study: NCT02597478
Drug: Fentanyl Sublingual Spray
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
Study: NCT01329562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo tablet matching Treximet for oral administration.
Study: NCT00002738
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03005015
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00352664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
Study: NCT05532306
Drug: Copegus® 200 mg film coated tablet (2*200mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immediate release film-coated tablet containing 200 mg Ribavirin
Study: NCT02038699
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
Study: NCT03868059
Drug: LPCN 1021
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
Study: NCT01970098
Drug: KPS-0373, High dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 weeks
Study: NCT01970098
Drug: KPS-0373, Low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 weeks
Study: NCT01970098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 weeks
Study: NCT04509661
Drug: LABA/LAMA or Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled LABA/LAMA for one year.
Study: NCT01719497
Drug: [C-11]OMAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radioligand
Study: NCT01305577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT02649751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo treatment is lactose capsule.
Study: NCT03120351
Drug: Lidoderm 5 % Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
Study: NCT03120351
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
Study: NCT01203982
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5mg/day for one year
Study: NCT01203982
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40mg/day for one year
Study: NCT04106206
Drug: LY3372689
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04106206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00241839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
Study: NCT00241839
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study: NCT02231931
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose, fasted
Study: NCT02231931
Drug: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasted
Study: NCT03066947
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose pre-treatment to reduce regulatory T cells
Study: NCT04420104
Drug: iv analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv contromal
Study: NCT00271453
Drug: Durogesic® (fentanyl transdermal drug delivery system)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01963078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01998165
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
Study: NCT00704119
Drug: RhuDex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Treatment A.1: 31.65 mg RhuDex® once N=12~* Treatment A.2: 63.33 mg RhuDex® once N=12~* Treatment A.3: 126.63 mg RhuDex® once N=12~* Treatment A.4: 253.26 mg RhuDex® once N=12~* Treatment B.1: 31.65 mg RhuDex® once N=12~* Treatment B.2: selected dose of RhuDex® once N=12~* Treatment C: selected dose of RhuDex® once N=12~* Treatment D: selected dose of RhuDex® twice daily for 6 days N=12
Study: NCT04462614
Drug: Decrease per-dialytic heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
Study: NCT03048578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Saline Solution
Study: NCT00390676
Drug: ADH -1 and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04487886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match duvelisib will be taken orally twice per day for 14 days.
Study: NCT02625909
Drug: SOF/VEL for 6 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
Study: NCT02625909
Drug: SOF/VEL for 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
Study: NCT01103193
Drug: remifentanil injected
Normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
Study: NCT03001817
Drug: Placebo (for K-877)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03001817
Drug: Placebo (for Fenofibrate)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03855059
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a saline solution of given IV or perineural.
Study: NCT00925457
Drug: Current proton pump inhibitor (PPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current PPI and not current dapoxetine
Study: NCT00379821
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
Study: NCT02284243
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01283282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO qday for 6 weeks
Study: NCT01339052
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618096
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01704482
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00083226
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01148992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg
Study: NCT00566696
Drug: Thioplex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study: NCT00909857
Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
Study: NCT00909857
Drug: Ethinyl estradiol, Levonorgestrel (Miranova)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
Study: NCT00566696
Drug: Rituxan™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study: NCT00566696
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study: NCT03369262
Drug: OBE022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03369262
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01847027
Drug: NutraStem
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Study: NCT01847027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Study: NCT02872935
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml of normal saline will be given intravenously with the administration of the spinal dose
Study: NCT00082797
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00082797
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02196662
Drug: IBD98-M:
Approvals — FDA: no, EMA: no, PMDA: no
Description: single adiministration
Study: NCT02196662
Drug: IBD98-M without HA
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: single adiministration
Study: NCT03414931
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator
Study: NCT02111304
Drug: iOWH032
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03734913
Drug: ZSP1602
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1602 capsules for oral administration
Study: NCT00532610
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03198624
Drug: HTL0018318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A single dose Part B five doses
Study: NCT03198624
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B only
Study: NCT02331277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04603027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT01619969
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of identical appearance containing starch
Study: NCT00994968
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00994968
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01282619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally twice a day
Study: NCT03291366
Drug: UCMSCC
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of aUCMSC and conventional therapy
Study: NCT03291366
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment
Study: NCT00854113
Drug: EGT0001474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ascending doses given daily as capsules for up to 14 days
Study: NCT00854113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EGT0001474
Study: NCT00942097
Drug: Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
Study: NCT00942097
Drug: Homeopathy and Nutritional oriented diet
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
Study: NCT04069897
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
Study: NCT02767349
Drug: MNK-155
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 3 tablets initial dose, followed by two tablets every twelve hours
Study: NCT03060980
Drug: ITCA 650 20/60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
Study: NCT01795170
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
Study: NCT00422864
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.